These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38058514)

  • 21. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib for the Treatment of Sarcoma.
    Blay JY; Duffaud F; George S; Maki RG; Penel N
    Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials.
    Liu R; Wei S; Zhang Q; Zhang X; Luo H; Tian J; Li Y; Ge L; Wang X
    Medicine (Baltimore); 2019 Jul; 98(29):e16427. PubMed ID: 31335695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
    Just MA; Van Mater D; Wagner LM
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29084. PubMed ID: 33894051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
    Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Mosca M; Conci N; Di Federico A; Tateo V; Favorito V; Zappi A; Gelsomino F; De Giglio A
    JCO Precis Oncol; 2023 May; 7():e2300073. PubMed ID: 37262392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zer A; Ding K; Lee SM; Goss GD; Seymour L; Ellis PM; Hackshaw A; Bradbury PA; Han L; O'Callaghan CJ; Tsao MS; Shepherd FA
    J Thorac Oncol; 2016 Mar; 11(3):312-23. PubMed ID: 26749487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
    Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
    Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.
    Xie L; Xu J; Guo W; Wang Z; Yao Y; Li J; Lin J; Xiao J; Yu X; Zhang W; Cai Z; Hua Y; Chen J; Shao Z; Wu D; Wu S; Tu Z; Zhang X
    Front Oncol; 2021; 11():696865. PubMed ID: 34367981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
    Liu J; Sheng Z; Zhang Y; Li G
    Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
    Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
    Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
    Zhang WQ; Li T; Li H
    Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.
    Zhang Z; Zhao Y; Lu F; Hou X; Ma Y; Luo F; Zeng K; Zhao S; Zhang Y; Zhou T; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Ann Transl Med; 2019 Sep; 7(18):452. PubMed ID: 31700888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
    Fluhrer H; Hutterer GC; Golbeck S; Stidl M; Niedrist T; Pichler R; Mischinger J; Seles M; Mannweiler S; Spiegelberg J; Bauernhofer T; Jost PJ; Ahyai S; Zigeuner R; Pichler M; Barth DA
    Ther Adv Med Oncol; 2022; 14():17588359221134065. PubMed ID: 36425872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.